Maintenance chemotherapy is typically continued until one of three things happens: the cancer starts growing again, side effects become too burdensome, or you and your oncologist agree that enough treatment has been given based on your specific cancer type and response. There is no single universal timeline. The answer depends heavily on what kind of cancer you have, how well you’ve responded, and how the treatment is affecting your daily life.
The Default Rule: Treat Until Progression
For many cancers, the standard approach is to continue maintenance therapy until the disease progresses. Progression usually means tumors are growing again on imaging scans, blood markers are rising, or new symptoms develop. Scans are typically done every 8 to 12 weeks during maintenance to catch this. If imaging shows a tumor growing by even a small amount, or if new sites of disease appear, that’s a clear signal to stop the current maintenance and discuss next steps.
But “treat until progression” is not the only valid strategy. A growing body of evidence shows that for certain cancers, planned treatment breaks or fixed durations of maintenance can be just as effective as indefinite therapy, with significantly fewer side effects.
Treatment Breaks Can Be Safe
In metastatic colorectal cancer, researchers have directly tested whether patients can stop maintenance chemotherapy entirely and simply be monitored closely. The FOCUS4-N trial randomly assigned 254 patients to either continue maintenance capecitabine or stop all treatment and undergo active monitoring instead. Overall survival was virtually identical: 15.2 months in the monitoring group versus 14.8 months in the maintenance group. A meta-analysis of similar trials reached the same conclusion: none showed a meaningful survival benefit from continuous maintenance over a planned break.
Patients who took the treatment break avoided the ongoing side effects of capecitabine, including fatigue, diarrhea, mouth sores, and hand-foot skin reactions. They were still closely watched with imaging every 8 to 12 weeks and regular symptom checks, so if the cancer started growing again, treatment could be restarted promptly. This kind of planned “chemotherapy holiday” is a legitimate option worth discussing with your oncologist, particularly in colorectal cancer.
Timelines Vary by Cancer Type
Different cancers have different conventions for how long maintenance lasts, and the landscape is still shifting.
Lung cancer: In advanced non-squamous lung cancer, a common approach combines an immunotherapy drug with pemetrexed as maintenance for up to 2 years after completing initial combination chemotherapy. Many patients stop pemetrexed earlier due to side effects, and researchers are actively re-evaluating whether the full 2-year course is necessary now that immunotherapy is part of the regimen.
Ovarian cancer: PARP inhibitors are widely used as maintenance after platinum-based chemotherapy. There is no consensus on how long to continue them. An international survey of oncologists found striking variation: some recommended 1 year, others 2 or 3 years, and nearly half recommended indefinite treatment for patients who continued to respond well. For patients who remain progression-free beyond 5 years, practice varies so widely that no single recommendation exists.
Multiple myeloma: Lenalidomide maintenance after stem cell transplant has traditionally been given indefinitely. However, newer research is challenging this. A study called MRD2STOP found that patients who achieved very deep responses, measured by extremely sensitive tests showing no detectable residual disease, could safely stop maintenance. In one trial, patients who tested negative for residual disease at the deepest measurable level after one year of maintenance had a 75% chance of remaining progression-free three years after stopping. Another trial found an 83% four-year progression-free rate after stopping at two years for patients with similarly deep responses.
Colorectal cancer: After 3 to 4 months of initial combination chemotherapy, patients who have at least stable disease typically step down to a simpler maintenance regimen or stop treatment altogether. Continuing the full combination regimen until progression offers no benefit over these lighter approaches.
When Side Effects Force the Decision
Cumulative toxicity is one of the most common reasons maintenance therapy ends in practice, regardless of what the protocol calls for. Side effects that seem manageable in the first cycle often compound over time. Research on targeted therapies found that a 20% to 30% risk of severe side effects in the first cycle translated into a 47% to 66% cumulative risk by the sixth cycle. The longer you stay on treatment, the more toxicity accumulates.
Cancer-related fatigue is particularly significant. Between 30% and 60% of patients undergoing treatment report moderate to severe fatigue, and in some cases this directly leads to treatment discontinuation. This isn’t just feeling tired. It can erode your ability to work, maintain relationships, and do the things that make life meaningful. Since one of the core goals of maintenance therapy is preserving quality of life, a treatment that significantly degrades your daily functioning may be defeating its own purpose.
Specific side effects that commonly trigger discontinuation include persistent low blood counts, nerve damage causing numbness or tingling in hands and feet, ongoing nausea, kidney or liver function changes, and skin reactions. Your oncologist will monitor bloodwork regularly and will typically pause or stop treatment if side effects reach a certain severity, even if the cancer itself is still responding.
How “Stopping” Actually Works
Stopping maintenance chemotherapy rarely means walking away from cancer care. In almost every scenario, whether you stop because of progression, toxicity, or a planned break, you transition into a structured monitoring phase. This includes regular imaging scans, bloodwork, and symptom assessments. If the cancer returns or grows, treatment can be restarted or switched to a different regimen.
For cancers like multiple myeloma, the decision to stop is increasingly guided by measurable residual disease testing, which detects cancer cells at extraordinarily low levels. Researchers have proposed that achieving negativity at less than one cancer cell per ten million normal cells could justify stopping maintenance or even skipping it entirely. This kind of precision monitoring is changing the conversation from “treat indefinitely” to “treat until we have evidence it’s safe to stop.”
What to Bring Up With Your Oncologist
The decision to stop maintenance chemotherapy is rarely black and white. Several factors feed into it, and you have a role in the conversation. Useful questions to raise include how your specific cancer type and molecular profile affect the expected duration, whether your response has been deep enough to consider stopping, what monitoring would look like after stopping, and how quickly treatment could restart if needed.
Your own experience matters in this decision. If treatment is significantly affecting your quality of life, that’s a legitimate and important data point, not a failure of willpower. The entire premise of maintenance therapy is to help you live longer and better. When the “better” part starts slipping, the calculus changes. In colorectal cancer, the evidence already supports complete treatment breaks with no survival penalty. In myeloma, deep-response testing is opening the door to guided discontinuation. In other cancers, the conversation is evolving rapidly, and your oncologist can help you weigh the specific trade-offs for your situation.